St. Charles Pharmaceuticals

St. Charles Pharmaceuticals is a clinical-stage biopharmaceutical company based in New Orleans, Louisiana, that focuses on developing topical treatments for chronic pain. The company's lead product candidate, SCP-1, is a proprietary topical cream formulation of ketamine and amitriptyline designed to treat various forms of neuropathic pain. By utilizing a topical delivery system, the company aims to provide localized analgesic effects while avoiding the systemic side effects typically associated with oral administration of these compounds. St. Charles Pharmaceuticals has evaluated SCP-1 in Phase 2 clinical trials for indications including diabetic peripheral neuropathy and post-herpetic neuralgia. The company was founded by a group of entrepreneurs and scientists, including the late James R. Moffett, and has historically collaborated with the LSU Health Sciences Center.